ReviewCancers2020
Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.Cell communication and signaling : CCS · 2024Review
- Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.Frontiers in immunology · 2024Article
- Clinical Characteristics and Outcomes in Hospitalized Patients with COVID-19 and Cancer History: A Multicenter Cross-Sectional Study in Southwestern Iran.International journal of hematology-oncology and stem cell research · 2024Article
- An Impact of COVID-19 on Cancer Care: An Update.Vaccines · 2022Review
- The Impact of COVID-19 Infection in Cancer 2020-2021.Cancers · 2022Article
- Manifestations of COVID-19 infection in children with malignancy: A single-center experience in Jordan.World journal of virology · 2022Article
- Article
- Prognostic serum biomarkers in cancer patients with COVID-19: A systematic review.Translational oncology · 2022Article
- SARS-CoV-2 M Protein Facilitates Malignant Transformation of Breast Cancer Cells.Frontiers in oncology · 2022Article
- COVID-19 infection in the cancer population: a study of emergency department imaging utilization and findings.Emergency radiology · 2021Article
- Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients.Scientific reports · 2021Article
- The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer.International journal of molecular sciences · 2021Review
- Endothelial cells and SARS-CoV-2: An intimate relationship.Vascular pharmacology · 2021Review
- Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.Inflammopharmacology · 2021Review
- A narrative review of the pathophysiology of COVID-19 infection among cancer patients: Current evidence and research perspectives.Health science reports · 2021Review
- A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020.International journal of environmental research and public health · 2021Article
- The Deadly Duo of COVID-19 and Cancer!Frontiers in molecular biosciences · 2021Review
- Mitigating strategies and nursing response for cancer care management during the COVID-19 pandemic: an Italian experience.International nursing review · 2020Article
- Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.Cancer medicine · 2020Article
- Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy).Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In late December 2019, a new infectious viral disease appeared. A new betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has been recognized as the pathogen responsible for this infection. Patients affected by tumors are more vulnerable to infection owing to poor health status, concomitant chronic diseases, and immunosuppressive conditions provoked by both the cancer and antitumor therapies. In this review, we have analyzed some lesser known aspects of the relationship between neoplasms and SARS-CoV-2 infection, starting from the different expression of the ACE2 receptor of the virus in the various neoplastic pathologies, and the roles that different cytokine patterns could have in vulnerability to infection and the appearance of complications. This review also reports the rationale for a possible use of drugs commonly employed in neoplastic therapy, such as bevacizumab, ibrutinib, selinexor, thalidomide, carfilzomib, and PD-1 inhibitors, for the treatment of SARS-CoV-2 infection. Finally, we have highlighted some diagnostic challenges in the recognition of SARS-CoV-2 infection in cancer-infected patients. The combination of these two health problems-tumors and a pandemic virus-could become a catastrophe if not correctly handled. Careful and judicious management of cancer patients with SARS-Cov-2 could support a better outcome for these patients during the current pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.